Titre :

Combining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experience.

Auteur(s) :

Crickx, Etienne [Auteur]
Immunogenetics of pediatric autoimmune diseases [Equipe Inserm U1163]
CHU Henri Mondor [Créteil]
Ebbo, Mikael [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Rivière, Etienne [Auteur]
Hôpital Haut-Lévêque [CHU Bordeaux]
Souchaud-Debouverie, Odile [Auteur]
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital [CHU de Poitiers [La Milétrie]]
Terriou, Louis [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Audia, Sylvain [Auteur]
CHU Dijon
Ruivard, Marc [Auteur]
CHU Clermont-Ferrand
Asli, Bouchra [Auteur]
Clinique de la Sauvegarde [Lyon]
Marolleau, Jean-Pierre [Auteur]
CHU Amiens-Picardie
Méaux-Ruault, Nadine [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Gerfaud-Valentin, Mathieu [Auteur]
Hôpital de la Croix-Rousse [CHU - HCL]
Audeguy, Philippe [Auteur]
Centre Hospitalier Eure-Seine - Hôpital d'Evreux - Vernon (Evreux)
Hamidou, Mohamed [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Corm, Selim [Auteur]
Delbrel, Xavier [Auteur]
Centre hospitalier de Pau
Fontan, Jean [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Lebon, Delphine [Auteur]
HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 [HEMATIM]
Mausservey, Christelle [Auteur]
Centre Hospitalier Chalon-sur-Saône William Morey
Moulis, Guillaume [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Limal, Nicolas [Auteur]
CHU Henri Mondor [Créteil]
Michel, Marc [Auteur]
CHU Henri Mondor [Créteil]
Godeau, Bertrand [Auteur]
CHU Henri Mondor [Créteil]
Mahévas, Matthieu [Auteur]
CHU Henri Mondor [Créteil]
Institut Necker Enfants-Malades [INEM - UM 111 (UMR 8253 / U1151)]

Titre de la revue :

British Journal of Haematology

Nom court de la revue :

Br J Haematol

Date de publication :

2023-05-31

ISSN :

1365-2141

Mot(s)-clé(s) en anglais :

combination therapy
immunosuppressive drug
ITP
TPO-RA

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Combining drugs could be an effective option for treating multirefractory ITP, that is, patients not responding to rituximab, thrombopoietin receptor agonists (TPO-RA) and splenectomy. We conducted a retrospective, ...
Lire la suite >Combining drugs could be an effective option for treating multirefractory ITP, that is, patients not responding to rituximab, thrombopoietin receptor agonists (TPO-RA) and splenectomy. We conducted a retrospective, multicenter, observational study including multirefractory ITP patients who received a combination of a TPO-RA and an immunosuppressive drug. We included 39 patients (67% women, median age 59 years [range 21-96]), with a median ITP duration of 57 months [3-393] and a median platelet count at initiation of 10 × 109 /L [1-35]. The combination regimen was given for a median duration of 12 months [1-103] and included eltrombopag (51%) or romiplostim (49%), associated with mycophenolate mofetil (54%), azathioprine (36%), cyclophosphamide (5%), cyclosporin (3%) or everolimus (3%). Overall, 30 patients (77%) achieved at least a response (platelet count ≥30 × 109 /L and at least doubling baseline during at least 3 months), including 24 complete responses (platelet count >100 × 109 /L during at least 3 months) with a median time to response of 30 days [7-270] and a median duration of response of 15 months [4-63]. Severe adverse event related to ITP treatment was observed in 31%. In conclusion, this study confirms that some patients with multirefractory ITP can achieve long lasting response with this combination.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-11T22:35:38Z
2024-02-27T14:02:01Z